Ascentage Pharma (ADR)
Develops and commercializes hematology therapies in China and global clinical trials.
Something off on this page? Send us feedback.
Breakdown13F · Form 4
Shares outstanding — · Float —
Shares outstanding and float — provider count disagrees with the price.
Insiders — filings are in the shares behind the receipt.
The provider's share count does not square with the market price, so neither it nor anything divided by it is shown.
This listing is a depositary receipt and the Form 4 positions here are filed in the shares behind it, a different unit from the share count and in a ratio the filings never state, so no insider percentage is shown.
The institutional figure is the one the filers report, not a quotient recomputed on the share count.
Institutions13F, as of Mar 31, 2026
6 holders · 30.2K shares · 0 new positions · 2 increased · 3 reduced · 5 closed
| Holder | Shares | % outstanding | Chg q/q | Filed |
|---|---|---|---|---|
| Point72 Asset Management, L.P. | 16.1K | −670 | May 15, 2026 | |
| XY Capital Ltd | 13.0K | −614 | May 12, 2026 | |
| Tower Research Capital LLC (TRC) | 518 | +288 | May 15, 2026 | |
| Morgan Stanley | 498 | +345 | May 15, 2026 | |
| UBS Group AG | 124 | −4.1K | May 5, 2026 | |
| Eversource Wealth Advisors, LLC | 24 | 0 | May 18, 2026 |
Beneficial owners13D/G · 5% or more, as filed
No 13D/G filer at 5% or more on record.
InsidersForm 4
No current Form 4 position on record.
10 positions are filed in the unlisted share unit (10.87M shares), which no share count here divides
Latest trades
No open-market trades in the last 12 months.
CongressHouse and Senate disclosures
Not reported.